Loading clinical trials...
Loading clinical trials...
An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients
Conditions
Interventions
Gelclair
First® Mouthwash BLM
Locations
2
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham & Women's Hospital/Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
May 15, 2018
Primary Completion Date
November 15, 2019
Completion Date
November 15, 2019
Last Updated
November 22, 2019
NCT05853692
NCT07040969
NCT06968520
NCT06390176
NCT07467759
NCT07287826
Lead Sponsor
Midatech Pharma US Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions